Allianz Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Allianz Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$442K	Sell	7,600 -1,800	-19%	-$82.9K	﹤0.01%	1853
2025 Q4	$421K	Hold	9,400	–	–	﹤0.01%	1856
2025 Q3	$377K	Hold	9,400	–	–	﹤0.01%	1896
2025 Q2	$294K	Hold	9,400	–	–	﹤0.01%	1908
2025 Q1	$315K	Sell	9,400 -3,000	-24%	-$114K	﹤0.01%	2023
2024 Q4	$486K	Buy	12,400 +4,300	+53%	+$178K	﹤0.01%	1873
2024 Q3	$319K	Sell	8,100 -2,900	-26%	-$117K	﹤0.01%	1976
2024 Q2	$429K	Sell	11,000 -6,400	-37%	-$256K	﹤0.01%	1882
2024 Q1	$749K	Hold	17,400	–	–	﹤0.01%	1500
2023 Q4	$801K	Buy	17,400 +4,200	+32%	+$148K	﹤0.01%	1689
2023 Q3	$451K	Hold	13,200	–	–	﹤0.01%	1960
2023 Q2	$508	Sell	13,200 -6,800	-34%	-$270K	﹤0.01%	2086
2023 Q1	$716K	Hold	20,000	–	–	﹤0.01%	1802
2022 Q4	$789K	Hold	20,000	–	–	﹤0.01%	1593
2022 Q3	$722K	Sell	20,000 -68,630	-77%	-$2.47M	﹤0.01%	1469
2022 Q2	$2.7M	Sell	88,630 -13,555	-13%	-$410K	﹤0.01%	1313
2022 Q1	$3.12M	Buy	102,185 +32,280	+46%	+$966K	﹤0.01%	1423
2021 Q4	$2.19M	Buy	+69,905	New	+$2.09M	﹤0.01%	1580

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Allianz Asset Management's XENE Position: Q1 2026 in Review

Allianz Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 19% in Q1 2026, selling an estimated $82.9K and leaving 7,600 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #1853.

Allianz Asset Management first reported a position in XENE in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.12M in Q1 2022. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Allianz Asset Management held 7,600 shares of Xenon Pharmaceuticals worth $442K as of Q1 2026.
Allianz Asset Management sold 1,800 Xenon Pharmaceuticals shares in Q1 2026, an estimated $82.9K.
Xenon Pharmaceuticals made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1853 holding.
Allianz Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Allianz Asset Management's Xenon Pharmaceuticals position peaked at $3.12M in Q1 2022.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.